{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T19:45:39Z","timestamp":1789933539444,"version":"4.0.1"},"reference-count":42,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1016\/j.clinthera.2014.10.019","type":"journal-article","created":{"date-parts":[[2014,11,22]],"date-time":"2014-11-22T12:21:19Z","timestamp":1416658879000},"page":"124-133","source":"Crossref","is-referenced-by-count":32,"title":["Real-world Analysis of Tyrosine Kinase Inhibitor Treatment Patterns Among Patients With Chronic Myeloid Leukemia in the United States"],"prefix":"10.1016","volume":"37","author":[{"given":"Henry J.","family":"Henk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mabel","family":"Woloj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Shapiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Whiteley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2014.10.019_bib1","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1038\/sj.leu.2402577","article-title":"Chronic myelogenous leukemia: mechanisms underlying disease progression","volume":"16","author":"Shet","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.clinthera.2014.10.019_bib2","unstructured":"American Cancer Society. How is chronic myeloid leukemia staged? http:\/\/www.cancer.org\/cancer\/leukemia-chronicmyeloidcml\/detailedguide\/leukemia-chronic-myeloid-myelogenous-staging. Accessed August 2, 2013."},{"key":"10.1016\/j.clinthera.2014.10.019_bib3","unstructured":"National Cancer Institute. Surveillance epidemiology and end results (SEER) fact sheet: Chronic myeloid leukemia. http:\/\/seer.cancer.gov\/statfacts\/html\/cmyl.html. Accessed July 27, 2013."},{"key":"10.1016\/j.clinthera.2014.10.019_bib4","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/1741-7015-9-99","article-title":"Advances in the treatment of chronic myeloid leukemia","volume":"9","author":"Eiring","year":"2011","journal-title":"BMC Med"},{"key":"10.1016\/j.clinthera.2014.10.019_bib5","first-page":"935","article-title":"R. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia","volume":"8","author":"Cohen","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clinthera.2014.10.019_bib6","first-page":"1972","article-title":"Approval summary: imatinib mesylate capsules for treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase","volume":"9","author":"Johnson","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clinthera.2014.10.019_bib7","first-page":"281","article-title":"Dasatinib in chronic myeloid leukemia: a review","volume":"5","author":"Aguilera","year":"2009","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.clinthera.2014.10.019_bib8","doi-asserted-by":"crossref","first-page":"5325","DOI":"10.1158\/1078-0432.CCR-08-0308","article-title":"Tasigna for chronic and accelerated phase Philadelphia chromosome-positive chronic myelogenous leukemia resistant to or intolerant of imatinib","volume":"14","author":"Hazarika","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clinthera.2014.10.019_bib9","unstructured":"National Cancer Institute. FDA Approval for Dasatinib. http:\/\/www.cancer.gov\/cancertopics\/druginfo\/fda-dasatinib. Accessed August 2, 2013."},{"key":"10.1016\/j.clinthera.2014.10.019_bib10","unstructured":"U.S. Food and Drug Administration. Nilotinib (Tasigna). http:\/\/www.fda.gov\/AboutFDA\/CentersOffices\/OfficeofMedicalProductsandTobacco\/CDER\/ucm216218.htm. Accessed August 2, 2013."},{"key":"10.1016\/j.clinthera.2014.10.019_bib11","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.leukres.2013.01.006","article-title":"Considerations for early switch to nilotinib or dasatinib in patients with chronic myeloid leukemia with inadequate response to first-line imatinib","volume":"37","author":"Quint\u00e1s-Cardama","year":"2013","journal-title":"Leuk Res"},{"key":"10.1016\/j.clinthera.2014.10.019_bib12","unstructured":"National Cancer Institute. FDA Approval for Bosutinib. http:\/\/www.cancer.gov\/cancertopics\/druginfo\/fda-bosutinib. Accessed December 16, 2013."},{"key":"10.1016\/j.clinthera.2014.10.019_bib13","unstructured":"U.S. Food and Drug Administration. Inclusig (ponatinib). http:\/\/www.fda.gov\/Drugs\/InformationOnDrugs\/ApprovedDrugs\/ucm373072.htm. Accessed December 16, 2013."},{"issue":"suppl 19","key":"10.1016\/j.clinthera.2014.10.019_bib14","first-page":"1","article-title":"Clinical roundtable monograph: emerging treatment options for TKI-resistant chronic myelogenous leukemia","volume":"10","author":"Cortes","year":"2012","journal-title":"Clin Adv Hematol Oncol"},{"key":"10.1016\/j.clinthera.2014.10.019_bib15","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/ajh.23180","article-title":"Patient adherence to tyrosine kinase inhibitor therapy in chronic myeloid leukemia","volume":"87","author":"Jabbour","year":"2012","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clinthera.2014.10.019_bib16","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"IRIS Investigators. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2014.10.019_bib17","unstructured":"Deininger M, O\u2019Brien SG, Guilhot F, et al. International randomized study of interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Abstract presented at: 51st ASH Annual Meeting and Exposition; December 5-8, 2009; New Orleans, LA."},{"key":"10.1016\/j.clinthera.2014.10.019_bib18","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1002\/cncr.20922","article-title":"Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up","volume":"103","author":"Lahaye","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.clinthera.2014.10.019_bib19","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1188\/09.CJON.523-534","article-title":"Treatment of chronic myeloid leukemia following imatinib resistance: a nursing guide to second-line treatment options","volume":"13","author":"Bauer","year":"2009","journal-title":"Clin J Oncol Nurs"},{"key":"10.1016\/j.clinthera.2014.10.019_bib20","doi-asserted-by":"crossref","first-page":"5143","DOI":"10.1182\/blood-2006-11-056028","article-title":"Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial","volume":"109","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2014.10.019_bib21","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1182\/blood-2006-09-047266","article-title":"Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy","volume":"109","author":"Hochhaus","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2014.10.019_bib22","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1182\/blood-2006-09-046888","article-title":"Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis","volume":"109","author":"Cortes","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2014.10.019_bib23","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1182\/blood-2010-03-277152","article-title":"Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results","volume":"117","author":"Kantarjian","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2014.10.019_bib24","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/leu.2012.181","article-title":"Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study","volume":"27","author":"Giles","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.clinthera.2014.10.019_bib25","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.1002\/cncr.24504","article-title":"Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R)","volume":"115","author":"Kantarjian","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.clinthera.2014.10.019_bib26","doi-asserted-by":"crossref","first-page":"3709","DOI":"10.1002\/cncr.24418","article-title":"Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase","volume":"115","author":"Alvarado","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.clinthera.2014.10.019_bib27","doi-asserted-by":"crossref","first-page":"4437","DOI":"10.1182\/blood-2008-06-162388","article-title":"European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor","volume":"112","author":"Marin","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2014.10.019_bib28","doi-asserted-by":"crossref","first-page":"e95","DOI":"10.1038\/bcj.2012.30","article-title":"Managing chronic myeloid leukemia patients intolerant to tyrosine kinase inhibitor therapy","volume":"2","author":"Deangelo","year":"2012","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clinthera.2014.10.019_bib29","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/MOH.0b013e3283366bcb","article-title":"Managing imatinib resistance in chronic myeloid leukaemia","volume":"17","author":"Osborn","year":"2010","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.clinthera.2014.10.019_bib30","doi-asserted-by":"crossref","first-page":"399","DOI":"10.3324\/haematol.2012.064337","article-title":"Outcome of 82 chronic myeloid leukemia patients treated with nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitors","volume":"98","author":"Russo Rossi","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.clinthera.2014.10.019_bib31","doi-asserted-by":"crossref","first-page":"4361","DOI":"10.1182\/blood-2009-05-221531","article-title":"The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up","volume":"114","author":"Garg","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2014.10.019_bib32","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","article-title":"Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib","volume":"28","author":"Marin","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2014.10.019_bib33","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1182\/blood-2010-10-309807","article-title":"Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy","volume":"117","author":"Ibrahim","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2014.10.019_bib34","doi-asserted-by":"crossref","first-page":"5401","DOI":"10.1182\/blood-2008-12-196543","article-title":"Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study","volume":"113","author":"Noens","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2014.10.019_bib35","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1159\/000345722","article-title":"Adherence to tyrosine kinase inhibitor therapy for chronic myeloid leukemia: a Brazilian single-center cohort","volume":"130","author":"de Almeida","year":"2013","journal-title":"Acta Haematol"},{"key":"10.1016\/j.clinthera.2014.10.019_bib36","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/bjc.2012.348","article-title":"Investigating factors associated with adherence behaviour in patients with chronic myeloid leukemia: an observational patient-centered outcome study","volume":"107","author":"Efficace","year":"2012","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clinthera.2014.10.019_bib37","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1185\/03007995.2011.649849","article-title":"Adherence to treatment with second-line therapies, dasatinib and nilotinib, in patients with chronic myeloid leukemia","volume":"28","author":"Yood","year":"2012","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clinthera.2014.10.019_bib38","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1185\/03007995.2012.741577","article-title":"Monitoring and switching patterns of patients with chronic myeloid leukemia treated with imatinib in community settings: a chart review analysis","volume":"28","author":"Chen","year":"2012","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clinthera.2014.10.019_bib39","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clinthera.2014.10.019_bib40","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s12185-012-1010-4","article-title":"Patient characteristics and treatment patterns in chronic myeloid leukemia: evidence from a multi-country retrospective medical record chart review study","volume":"95","author":"Mitra","year":"2012","journal-title":"Int J Hematol"},{"key":"10.1016\/j.clinthera.2014.10.019_bib41","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2165\/00019053-200725060-00004","article-title":"Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia","volume":"25","author":"Darkow","year":"2007","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.clinthera.2014.10.019_bib42","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1185\/03007995.2012.705264","article-title":"A retrospective analysis of therapy adherence in imatinib resistant or intolerant patients with chronic myeloid leukemia receiving nilotinib or dasatinib in a real-world setting","volume":"28","author":"Gu\u00e9rin","year":"2012","journal-title":"Curr Med Res Opin"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291814006924?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291814006924?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,27]],"date-time":"2018-09-27T13:58:25Z","timestamp":1538056705000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291814006924"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["S0149291814006924"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2014.10.019","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2015,1]]}}}